NDA 212123 · Avid Radiopharms INC
Tauvid
Flortaucipir F-18 · Intravenous
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Feb 5, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2020
May 28, 2020
Approved uses
1
Original approval plus efficacy supplements
Registered trials
23
4 Phase 3, 4 recruiting
FAERS reports
1
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Dec 30, 2025.
TAUVID is indicated for use with positron emission tomography (PET) imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles (NFTs) in adult patients with cognitive impairment who are being evaluated for Alzheimer's disease (AD). TAUVID is a radioactive diagnostic agent indicated for positron emission tomography (PET) imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles (NFTs) in adult patients with cognitive impairment who are being evaluated for Alzheimer's disease (AD). ( 1 ) Limitations of Use TAUVID is not indicated for use in the evaluation of patients for chronic traumatic encephalopathy (CTE). ( 1 , 5.2 ) Limitations of Use TAUVID is not indicated for use in the evaluation of patients for chronic traumatic encephalopathy (CTE) [see Warnings and Precautions ( 5.2 )] .
Mechanism: Flortaucipir F 18 binds to aggregated tau protein. In the brains of patients with AD, tau aggregates combine to form NFTs, one of two components required for the neuropathological diagnosis of AD. In vitro , flortaucipir F 18 binds to paired helical filament (PHF) tau purified from brain homogenates of donors with AD. The dissociation constant (Kd) of flortaucipir F 18 binding to PHFs is 0.57 nM. In vivo , flortaucipir F 18 is differentially retained in neocortical areas that contain aggregated tau. In vitro , tritiated flortaucipir has been reported to bind with low nanomolar affinity to...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 28, 2020 Original approval · Type 1 - New Molecular Entity · priority review NovelLabelLetterReview
4 products under this application
- TAUVID · FLORTAUCIPIR F-18 100ML (8.1-100mCi/ML) · SOLUTION, INTRAVENOUS · Prescription
- TAUVID · FLORTAUCIPIR F-18 50ML (8.1-51mCi/ML) · SOLUTION, INTRAVENOUS · Discontinued
- TAUVID · FLORTAUCIPIR F-18 50ML (8.1-100mCi/ML) · SOLUTION, INTRAVENOUS · Prescription
- TAUVID · FLORTAUCIPIR F-18 30ML (8.1-51mCi/ML) · SOLUTION, INTRAVENOUS · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Flortaucipir F-18" as an intervention, any sponsor and status, largest first.
- Analysis of 18F-AV-1451 PET Imaging in Cognitively Healthy, MCI, and AD SubjectsPivotal-lookingCompleted
Avid RadiopharmaceuticalsIndustry
NCT02016560 · 383 participants · Start Dec 2013 · Primary completion Jul 28, 2017
Drug: florbetapir F 18; Flortaucipir F18 · For: Alzheimer's Disease
Sites: Phoenix, Arizona; Scottsdale, Arizona; Sun City, Arizona · 27 sites in all
- NFL LONG Prospective StudyActive, not recruiting
University of North Carolina, Chapel HillAcademic, hospital or other
NCT04263337 · 250 participants (planned) · Start Mar 12, 2020 · Primary completion Aug 2028
Drug: [11C] PiB; [18F] PBR111 and 1 more · For: Concussion, Brain
Sites: Waltham, Massachusetts; Chapel Hill, North Carolina; Milwaukee, Wisconsin
- A Reader Study to Assess Accuracy and Reliability of Flortaucipir F 18 Positron Emission Tomography (PET) Scan InterpretationPivotal-lookingCompleted
Avid RadiopharmaceuticalsIndustry
NCT03901092 · 242 participants · Start Mar 26, 2019 · Primary completion Apr 26, 2019
Drug: flortaucipir F 18 · For: Alzheimer Disease
Sites: Philadelphia, Pennsylvania
- Evaluation of Flortaucipir PET Signal and Cognitive Change in Early Alzheimer's DiseasePivotal-lookingCompleted
Avid RadiopharmaceuticalsIndustry
NCT03901105 · 205 participants · Start Mar 28, 2019 · Primary completion Apr 28, 2019
Drug: flortaucipir F18 · For: Alzheimer Disease
Sites: Philadelphia, Pennsylvania
Avid RadiopharmaceuticalsIndustry
NCT02278367 · 179 participants · Start Dec 2014 · Primary completion Jun 26, 2019
Drug: Flortaucipir F18 · For: Alzheimer's Disease; Traumatic Brain Injury; Depression
Sites: Phoenix, Arizona; New Haven, Connecticut; Las Vegas, Nevada · 5 sites in all
Avid RadiopharmaceuticalsIndustry
NCT03467477 · 161 participants · Start Mar 8, 2018 · Primary completion Nov 15, 2018
Drug: Flortaucipir F18 · For: Alzheimer Disease
Sites: Irvine, California; Delray Beach, Florida; Fort Myers, Florida · 9 sites in all
- 18F-AV-1451 Autopsy StudyPivotal-lookingCompleted
Avid RadiopharmaceuticalsIndustry
NCT02516046 · 156 participants · Start Sep 2015 · Primary completion Jun 13, 2018
Drug: Flortaucipir F18 · For: Alzheimer's Disease
Sites: Phoenix, Arizona; Los Gatos, California; Newport Beach, California · 31 sites in all
Avid RadiopharmaceuticalsIndustry
NCT03322462 · 155 participants · Start Nov 21, 2017 · Primary completion Aug 31, 2018
Drug: Flortaucipir F18 · For: Alzheimer Disease
Sites: San Diego, California; Santa Ana, California; Delray Beach, Florida · 10 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- incorrect dose administered1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2025 | 1 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Plasma pTau217 ratio predicts continuous regional brain tau accumulation in amyloid-positive early Alzheimer's disease.
Devanarayan V, Charil A, Horie K, et al. · Alzheimers Dement 2025 · Clinical Trial, Phase III, Multicenter Study
- Comparison of [18F]flortaucipir and [18F]MK6240 for the detection of tau pathology in Alzheimer's disease (HEAD): a multicentre, prospective, cross-sectional, within-participant study.
Povala G, Bellaver B, Lussier FZ, et al. · Lancet 2026 · Clinical Trial, Phase I, Comparative Study
Sponsor: Avid Radiopharms INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.